208 related articles for article (PubMed ID: 16084644)
1. Transcriptional profiling of a mouse model for Lafora disease reveals dysregulation of genes involved in the expression and modification of proteins.
Ganesh S; Tsurutani N; Amano K; Mittal S; Uchikawa C; Delgado-Escueta AV; Yamakawa K
Neurosci Lett; 2005 Oct; 387(2):62-7. PubMed ID: 16084644
[TBL] [Abstract][Full Text] [Related]
2. Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.
Ki CS; Kong SY; Seo DW; Hong SB; Kim HJ; Kim JW
J Hum Genet; 2003; 48(1):51-4. PubMed ID: 12560877
[TBL] [Abstract][Full Text] [Related]
3. Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease.
Puri R; Suzuki T; Yamakawa K; Ganesh S
Hum Mol Genet; 2012 Jan; 21(1):175-84. PubMed ID: 21965301
[TBL] [Abstract][Full Text] [Related]
4. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Gómez-Garre P; Sanz Y; Rodríguez De Córdoba SR; Serratosa JM
Eur J Hum Genet; 2000 Dec; 8(12):946-54. PubMed ID: 11175283
[TBL] [Abstract][Full Text] [Related]
5. Regional and developmental expression of Epm2a gene and its evolutionary conservation.
Ganesh S; Agarwala KL; Amano K; Suzuki T; Delgado-Escueta AV; Yamakawa K
Biochem Biophys Res Commun; 2001 May; 283(5):1046-53. PubMed ID: 11355878
[TBL] [Abstract][Full Text] [Related]
6. [Molecular genetics of epilepsy].
Yamakawa K
Rinsho Shinkeigaku; 2004 Nov; 44(11):858-60. PubMed ID: 15651314
[TBL] [Abstract][Full Text] [Related]
7. Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.
Ganesh S; Shoda K; Amano K; Uchiyama A; Kumada S; Moriyama N; Hirose S; Yamakawa K
Mol Cell Probes; 2001 Oct; 15(5):281-9. PubMed ID: 11735300
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome analysis reveals altered cholesterol metabolism during the neurodegeneration in mouse scrapie model.
Xiang W; Hummel M; Mitteregger G; Pace C; Windl O; Mansmann U; Kretzschmar HA
J Neurochem; 2007 Aug; 102(3):834-47. PubMed ID: 17437544
[TBL] [Abstract][Full Text] [Related]
9. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA
Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711
[TBL] [Abstract][Full Text] [Related]
10. Expression changes in mouse brains following nicotine-induced seizures: the modulation of transcription factor networks.
Kedmi M; Orr-Urtreger A
Physiol Genomics; 2007 Aug; 30(3):242-52. PubMed ID: 17456735
[TBL] [Abstract][Full Text] [Related]
11. Glycogen hyperphosphorylation underlies lafora body formation.
Turnbull J; Wang P; Girard JM; Ruggieri A; Wang TJ; Draginov AG; Kameka AP; Pencea N; Zhao X; Ackerley CA; Minassian BA
Ann Neurol; 2010 Dec; 68(6):925-33. PubMed ID: 21077101
[TBL] [Abstract][Full Text] [Related]
12. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S
Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976
[TBL] [Abstract][Full Text] [Related]
13. Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Vernia S; Heredia M; Criado O; Rodriguez de Cordoba S; Garcia-Roves PM; Cansell C; Denis R; Luquet S; Foufelle F; Ferre P; Sanz P
Hum Mol Genet; 2011 Jul; 20(13):2571-84. PubMed ID: 21493628
[TBL] [Abstract][Full Text] [Related]
14. The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
Ganesh S; Tsurutani N; Suzuki T; Ueda K; Agarwala KL; Osada H; Delgado-Escueta AV; Yamakawa K
Hum Mol Genet; 2003 Sep; 12(18):2359-68. PubMed ID: 12915448
[TBL] [Abstract][Full Text] [Related]
15. Microarray gene expression profiling of mouse brain mRNA in a model of lithium treatment.
Chetcuti A; Adams LJ; Mitchell PB; Schofield PR
Psychiatr Genet; 2008 Apr; 18(2):64-72. PubMed ID: 18349697
[TBL] [Abstract][Full Text] [Related]
16. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.
Ganesh S; Tsurutani N; Suzuki T; Hoshii Y; Ishihara T; Delgado-Escueta AV; Yamakawa K
Biochem Biophys Res Commun; 2004 Jan; 313(4):1101-9. PubMed ID: 14706656
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy.
Ganesh S; Puri R; Singh S; Mittal S; Dubey D
J Hum Genet; 2006; 51(1):1-8. PubMed ID: 16311711
[TBL] [Abstract][Full Text] [Related]
18. Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Trujillo-Tiebas MJ; Fenollar-Cortés M; Gómez-Garré P; Lorda-Sánchez I; Serratosa JM; Ayuso García C
Hum Genet; 2007 Jun; 121(5):651. PubMed ID: 17879451
[No Abstract] [Full Text] [Related]
19. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease.
Minassian BA
Adv Neurol; 2002; 89():199-210. PubMed ID: 11968446
[No Abstract] [Full Text] [Related]
20. Laforin in autophagy: a possible link between carbohydrate and protein in Lafora disease?
Puri R; Ganesh S
Autophagy; 2010 Nov; 6(8):1229-31. PubMed ID: 20818153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
